San Diego-based Anaphore said today it has raised $13 million in a second closing of its Series A preferred stock financing, bringing the round to a total of $38 million. Anaphore, founded in 2008, is developing a new class of protein therapeutics for life-threatening diseases. The company’s investors are the SR One venture unit of GlaxoSmithKline, Merck Serono Ventures, Aravis, 5AM Ventures, Versant Ventures, and Apposite Capital.